|
Diggs CH, Scoltock MJ, Wiernik PH.
Phase II evaluation of diacetoxyscirpenol
(anguidine) (NSC-141537) for adenocarcinoma of the colon or
rectum.
Cancer Clin Trials. 1978 Winter;1(4):297-9.
Anguidine was administered in a dose of 5.0
mg/m2 (3.5 mg/m2 for patients with hepatic dysfunction)
intravenously daily for 5 days in a phase II evaluation of
19 patients with metastatic adenocarcinoma of the colon or
rectum. Courses were repeated every 3 weeks. No responses
were observed but five patients had disease stabilization.
Toxicity was marked, causing discontinuation of therapy in
several patients. Anguidine appears ineffective in patients
with metastatic colon or rectal cancer in the dose and
schedule used in this study.
PMID: 757146
|
